Technology Bundle ID: TAB-2666

Novel Targets to Prevent Borrelia burgdorferi Infection and Lyme Disease

Request More Info
Primary Inventors: 
Robert Gilmore (CDC)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 
CDC

B. burgdorferi-infected ticks can cause Lyme disease in mammalian hosts. This technology relates to the use of B. burgdorferi outer surface proteins (BBA64 and BBA66) as Lyme disease vaccine candidates. In vivo animal studies demonstrate these outer surface proteins inhibit tick-to-host B. burgdorferi transmission. Presently, there is no vaccine approved for Lyme disease.

Applications:
  • B. burgdorferi/Lyme disease vaccine development
  • B. burgdorferi diagnostics
  • Prevention of B. burgdorferi infection by passive immunity
  • Zoonotic/tick-borne disease surveillance
  • Public health vaccination programs against Lyme disease
Advantages:
  • Currently no approved Lyme disease vaccines

Patents

US Application 61/814,741
Filed on 2013-04-22

Publications

Brandt KS, et al.
PMID 24501342
Gilmore RD Jr, et al.
PMID 17371862
Gilmore RD Jr, et al.
PMID 18848981
Gilmore RD Jr, et al.
PMID 20368453
Patton TG, et al.
PMID 21559293
Patton TG, et al.
PMID 23630963

Updated

Oct 23, 2013

Data Source: 
tts